Literature DB >> 21505839

[Diabetic retinopathy and maculopathy].

H-P Hammes1.   

Abstract

Diabetic retinopathy is the most frequent microvascular complication in diabetes. Its early development indicates an increased cardiovascular risk. Since the early stages lack symptoms, yearly screening intervals are mandatory. Each retinopathy level determines evidence-based treatment with mutual interactive contributions from diabetology and ophthalmology. Intravitreal injection of inhibitors of the vascular endothelial growth factor may improve the so far only modestly successful therapy of diabetic macular edema.

Entities:  

Mesh:

Year:  2011        PMID: 21505839     DOI: 10.1007/s00108-010-2762-7

Source DB:  PubMed          Journal:  Internist (Berl)        ISSN: 0020-9554            Impact factor:   0.743


  58 in total

1.  [Population-based study of diabetic retinopathy in Wolfsburg].

Authors:  L Hesse; M Grüsser; K Hoffstadt; V Jörgens; P Hartmann; P Kroll
Journal:  Ophthalmologe       Date:  2001-11       Impact factor: 1.059

2.  Association of ocular disease and mortality in a diabetic population.

Authors:  R Klein; B E Klein; S E Moss; K J Cruickshanks
Journal:  Arch Ophthalmol       Date:  1999-11

3.  Effect of lisinopril on progression of retinopathy in normotensive people with type 1 diabetes. The EUCLID Study Group. EURODIAB Controlled Trial of Lisinopril in Insulin-Dependent Diabetes Mellitus.

Authors:  N Chaturvedi; A K Sjolie; J M Stephenson; H Abrahamian; M Keipes; A Castellarin; Z Rogulja-Pepeonik; J H Fuller
Journal:  Lancet       Date:  1998-01-03       Impact factor: 79.321

4.  Prevalence and significance of retinopathy in subjects with type 1 diabetes of less than 5 years' duration screened for the diabetes control and complications trial.

Authors:  J I Malone; A D Morrison; P R Pavan; D D Cuthbertson
Journal:  Diabetes Care       Date:  2001-03       Impact factor: 19.112

5.  Effect of fenofibrate on the need for laser treatment for diabetic retinopathy (FIELD study): a randomised controlled trial.

Authors:  A C Keech; P Mitchell; P A Summanen; J O'Day; T M E Davis; M S Moffitt; M-R Taskinen; R J Simes; D Tse; E Williamson; A Merrifield; L T Laatikainen; M C d'Emden; D C Crimet; R L O'Connell; P G Colman
Journal:  Lancet       Date:  2007-11-07       Impact factor: 79.321

6.  Promoter polymorphism of the erythropoietin gene in severe diabetic eye and kidney complications.

Authors:  Zongzhong Tong; Zhenglin Yang; Shrena Patel; Haoyu Chen; Daniel Gibbs; Xian Yang; Vincent S Hau; Yuuki Kaminoh; Jennifer Harmon; Erik Pearson; Jeanette Buehler; Yuhong Chen; Baifeng Yu; Nicholas H Tinkham; Norman A Zabriskie; Jiexi Zeng; Ling Luo; Jennifer K Sun; Manvi Prakash; Rola N Hamam; Stephen Tonna; Ryan Constantine; Cecinio C Ronquillo; SriniVas Sadda; Robert L Avery; John M Brand; Nyall London; Alfred L Anduze; George L King; Paul S Bernstein; Scott Watkins; Lynn B Jorde; Dean Y Li; Lloyd Paul Aiello; Martin R Pollak; Kang Zhang
Journal:  Proc Natl Acad Sci U S A       Date:  2008-05-05       Impact factor: 11.205

7.  Cigarette smoking and ten-year progression of diabetic retinopathy.

Authors:  S E Moss; R Klein; B E Klein
Journal:  Ophthalmology       Date:  1996-09       Impact factor: 12.079

8.  The Wisconsin Epidemiologic Study of Diabetic Retinopathy: XVII. The 14-year incidence and progression of diabetic retinopathy and associated risk factors in type 1 diabetes.

Authors:  R Klein; B E Klein; S E Moss; K J Cruickshanks
Journal:  Ophthalmology       Date:  1998-10       Impact factor: 12.079

Review 9.  Optical coherence tomography versus stereoscopic fundus photography or biomicroscopy for diagnosing diabetic macular edema: a systematic review.

Authors:  Gianni Virgili; Francesca Menchini; Andrea F Dimastrogiovanni; Emilio Rapizzi; Ugo Menchini; Francesco Bandello; Raffaella Gortana Chiodini
Journal:  Invest Ophthalmol Vis Sci       Date:  2007-11       Impact factor: 4.799

Review 10.  Diabetic retinopathy and systemic vascular complications.

Authors:  Ning Cheung; Tien Y Wong
Journal:  Prog Retin Eye Res       Date:  2007-12-08       Impact factor: 21.198

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.